Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers

The American Journal of Psychiatry
Juan Francisco ArtaloytiaTomás Palomo

Abstract

Despite the clinical observation that antipsychotics can produce negative symptoms, no previous controlled study, to our knowledge, has evaluated this action in healthy subjects. The present study assessed observer-rated and self-rated negative symptoms produced by conventional and second-generation antipsychotics in healthy volunteers. The authors used a double-blind, placebo-controlled trial of single doses of haloperidol (5 mg) and risperidone (2.5 mg) in normal subjects. Thirty-two subjects were administered haloperidol, risperidone, and placebo in a random order. Motor variables and observer-rated negative symptoms were assessed after 3-4 hours and subjective negative symptoms and drowsiness after 24 hours. Neither of the active drugs caused significant motor extrapyramidal symptoms after administration. Haloperidol caused significantly more negative signs and symptoms than placebo on the Scale for the Assessment of Negative Symptoms (SANS) and two self-rated negative symptom scales: the Subjective Deficit Syndrome Scale total score and an analog scale that evaluates subjective negative symptoms. Risperidone caused significantly more negative signs and symptoms than placebo on the Brief Psychiatric Rating Scale (BPRS), the...Continue Reading

Citations

Aug 2, 2006·Current Psychiatry Reports·Daniel H Wolf
Aug 4, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Anthony P MorrisonDouglas Turkington
Jan 20, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·L Lladó-PelfortP Celada
Jan 20, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C ArangoUNKNOWN ZIS Study Group
Aug 26, 2006·Schizophrenia Research·Brendan P MurphyPatrick D McGorry
Jan 25, 2014·Schizophrenia Research·Alexander R DarosJohn A Sweeney
Dec 2, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·John D SalamonePhilip McGuire
Aug 14, 2013·Schizophrenia Research·Celso ArangoStephen R Marder
Jan 9, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gagan FervahaGary Remington
Sep 17, 2013·Neuroscience and Biobehavioral Reviews·Gagan FervahaGary Remington
Mar 5, 2013·Journal of Behavior Therapy and Experimental Psychiatry·Anton B P StaringMark van der Gaag
Feb 18, 2010·The International Journal of Neuropsychopharmacology·Analía BortolozziFrancesc Artigas
Aug 13, 2010·The International Journal of Neuropsychopharmacology·Mercè MasanaFrancesc Artigas
Mar 19, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·G FervahaG Remington
May 18, 2016·Brain : a Journal of Neurology·John D SalamoneMercè Correa
May 26, 2016·Schizophrenia Bulletin·Mark ShevlinJamie Murphy
May 28, 2016·Schizophrenia Research·Matthias KirschnerStefan Kaiser
Jul 28, 2016·Biological Psychiatry·Tiago V Maia, Michael J Frank
Jun 14, 2016·Schizophrenia Research·André AlemanHenderikus Knegtering
Oct 14, 2016·Schizophrenia Research·Ana M Sánchez-TorresManuel J Cuesta
Oct 26, 2016·Revista de psiquiatrí́a y salud mental·Benedicto Crespo-FacorroCelso Arango
Jul 18, 2012·The Australian and New Zealand Journal of Psychiatry·Anthony F Jorm
Feb 15, 2017·The Australian and New Zealand Journal of Psychiatry·Svein R KjosavikElisabeth E Roughead
Jul 22, 2008·Arquivos de neuro-psiquiatria·Henrique Cerqueira GuimarãesPaulo Caramelli
Jun 4, 2010·Journal of Clinical Psychopharmacology·Sebastian WaltherWerner Strik
Jun 13, 2019·Basic & Clinical Pharmacology & Toxicology·Pedro R OlivettiChristoph Kellendonk
Sep 17, 2019·European Psychiatry : the Journal of the Association of European Psychiatrists·S A StrejilevichM R Goldfarb
Jun 4, 2017·European Archives of Psychiatry and Clinical Neuroscience·Aida FarrenyStefan Priebe

❮ Previous
Next ❯

Methods Mentioned

BETA
SANS
sedation

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Schizophrenia Bulletin
Brian KirkpatrickStephen R Marder
The New England Journal of Medicine
Jeffrey A LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
European Psychiatry : the Journal of the Association of European Psychiatrists
Celso ArangoW T Carpenter
© 2021 Meta ULC. All rights reserved